Human kallikrein 11 (hK11/trypsin-like serine protease/ TLSP, encoded by the KLK11 gene) is a member of the kallikrein family of secreted serine proteases. Recently, we developed a highly sensitive and specific immunoassay for hK11 and found that this protease is expressed in the prostate, stomach and trachea as well as in amniotic fluid and milk of lactating women. Elevated serum hK11 levels were found in 60% of men with prostate cancer and 70% of women with ovarian cancer. Also, hK11 expression was found to be under the regulation of steroid hormones, particularly estrogens, at the level of KLK11 transcription. We hypothesized that hK11 may be implicated in endocrine-related malignancies and serve as a novel prostate and ovarian cancer serological marker. The aim of our study was to examine if hK11 Similarly, in the subgroup of patients with grade 1-2 tumors, hK11-positivity was associated with higher OS in both univariate and multivariate analysis (HR of 0.23 and 0.17, p < 0.05). Finally, in women with optimal debulking after surgery (<1 cm residual tumor), hK11 positivity was associated with a slower disease progression. These results indicate that hK11 is a novel, independent marker of favorable prognosis in patients with ovarian cancer.
Ovarian cancer is the sixth most common malignancy among women worldwide, accounting for 4.4% of female cancers and the most lethal of all gynecological cancers. 1, 2 Since ovarian carcinomas initially generate common and transient nonspecific symptoms, their prompt diagnosis is difficult. Over two-thirds of ovarian tumors are discovered at advanced International Federation of Gynecologists and Obstetricians (FIGO) Stages III/IV, when 5-year survival rates after treatment are only 18%. 3 When diagnosed at FIGO Stages I/II, this figure increases to 87%.
In addition to pelvic examination and transvaginal ultrasound, tumor markers contribute to the screening, diagnosis and monitoring of this malignancy, and represent important prognostic variables that aid in predicting response to therapy and disease recurrence. 4 The most extensively studied serological ovarian cancer marker is CA125. 5 Due to its limitations as a diagnostic, prognostic and screening tool, other biomarkers have been identified. 5, 6 Among these are CA19-9, CA15-3, TAG-72, OVX1, HER2, inhibin, the free ␤ subunit of human chorionic gonadotropin (HCG␤) and CYFRA 21-1 [7] [8] [9] [10] [11] as well as serine proteases including prostasin 12 and several members of the human tissue kallikrein family.
Human tissue kallikreins (hKs) are serine proteases encoded by 15 structurally similar genes that colocalize to chromosome 19q13.4. 13 Accumulating evidence indicates that many kallikreins are differentially expressed in hormone-dependent cancers including prostate, 14 -16 testicular, 17 breast 18, 19 and ovarian 20 -25 tumors and several possess prognostic value. 13 In addition to prostate specific antigen (PSA)/hK3, the best tumor marker available in clinical medicine, 26 other kallikreins such as hK6, 10 and 11 have emerged as potential serological epithelial ovarian cancer markers. [27] [28] [29] [30] Human kallikrein gene 11 (KLK11) was cloned using polymerase chain reaction (PCR) based assays from human hippocampus cDNA 31 and was subsequently recognized as a novel member of the kallikrein gene family. 32 Its protein product, hK11, which was previously referred to as trypsin-like serine protease (TLSP) and protease serine 20 (PRSS20), encodes for a serine protease of 260 amino acids in length. Of these 260, 18 amino acids constitute the signal peptide and 3 amino acids, the activation peptide. hK11 shares 41-51% identity with other kallikreins including PSA. 32 Recently, a highly sensitive and specific immunofluorometric assay for hK11 was developed and used to determine the distribution of this kallikrein in human tissues and biologic fluids and study its clinical utility. 29 hK11 was found to be expressed in the ovary, prostate, stomach, trachea, skin and colon and in seminal plasma, amniotic fluid and milk of lactating women. Preliminary evidence indicates that serum hK11 levels are elevated in 70% (14 out of 20 samples) of women with ovarian carcinoma, implying that this kallikrein may be a novel serological marker for ovarian cancer. Immunohistochemic analysis demonstrated that hK11 is present in the cytoplasm of epithelial cells derived from invasive papillary serous carcinoma of the ovary. 29 Also, similar to other kallikreins, the KLK11 gene was found to be upregulated by estradiol in 2 breast cancer cell lines, 29 further suggesting a role for this protease in endocrine-related malignancies. The aim of our study, given the above, was to determine if hK11 expression in ovarian tumors bears any prognostic significance.
MATERIAL AND METHODS

Ovarian cancer patients and specimens
A total of 104 patients with primary ovarian cancer were examined in our study, ranging in age from 25-81 years, with a median age of 59 (Table 1) . These patients underwent surgery and treatment for ovarian cancer at the Department of Gynecology of the University of Turin, Turin, Italy between July of 1991 and April of 1999. Histologic examination, performed during intrasurgery frozen section analysis, allowed representative portions of each tumor containing more than 80% tumor cells to be selected for storage until analysis. Patients were monitored for survival and disease progression (no apparent progression or progression) for a median duration of 67 months. Follow-up information was available for 92 patients, among which 52 (56%) had relapsed and 32 (33%) had died.
Clinical and pathologic information documented at the time of surgery included tumor stage, grade, histotype, residual tumor size, debulking success, menopausal status and response to chemotherapy ( Table 2 ). The staging of tumors was in accordance with the FIGO criteria, 33 grading was established according to Day et al. 34 and the classification of histotypes was based on the WHO and FIGO recommendations. 35 Patients with disease at all clinical stages (I-IV) and grades (1-3) were represented in our study. Of the 104 ovarian tumors, the majority (53; 52%) were of the serous papillary histotype, followed by endometriod (18; 17%), undifferentiated (14; 13%), clear cell (7; 7%), mucinous (4; 4%) or were unclassified (8; 7%). The residual size of tumors ranged from 0 -9 cm, with a median of 1.5 cm.
Investigations were carried out in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 1983, and were approved by the Institute of Obstetrics and Gynecology, Turin, Italy.
Preparation of cytosolic extracts
Tumor specimens were snap-frozen in liquid nitrogen immediately after surgery and stored at -80°C until extraction. Frozen tissues (20 -100 mg) were pulverized on dry ice to a fine powder and added to 10 volumes of extraction buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM EDTA, 10 g/L of NP-40 surfactant, 1 mM phenylmethyl sulphonyl fluoride, 1 g/L of aprotinin, 1 g/L of leupeptin). The resulting suspensions were incubated on ice for 30 min, with repeated shaking and vortexing every 10 min. The mixtures were then centrifuged at 10,000g at 4°C for 30 min and the supernatant (cytosolic extract) was collected and stored at -80°C until further analysis. Protein concentration of the extracts was determined using the bicinchoninic acid method, with albumin as standard (Pierce Chemical Co., Rockford, IL).
Measurement of hK11 in ovarian cytosolic extracts
The concentration of hK11 in the cytosolic extracts was quantified using a highly sensitive and specific noncompetitive immunoassay for hK11 that was previously described and evaluated. 29 Briefly, a mouse anti-hK11 monoclonal antibody was captured with sheep antimouse IgG, Fc fragment-specific antibodies (Jackson Immunoresearch, West Grove, PA), on 96-well polystyrene micortiter plates. hK11 calibrators (recombinant hK11 in 60 g/L BSA) or cytosolic extracts (100L) were then applied to each well in duplicate, incubated for 2 hr with gentle shaking and then washed. Rabbit anti-hK11 polyclonal antiserum was subsequently applied, incubated and washed. Finally, alkaline phosphatase-conjugated goat anti-rabbit IgG (Jackson Immunoresearch) was added, incubated and washed as before. Signal detection and data reduction were performed automatically by the CyberFluor 615 Immunoanalyzer (Nordion International, Kanata, Canada) which uses time resolved fluorometry, as described elsewhere. 36 The detection range of this assay is 0.1-50 g/L. hK11 concentrations in g/L were converted to ng of hK11/mg of total protein to adjust for the amount of tumor tissue extracted.
Statistical analysis
Statistical analysis was performed with SPSS software (SPSS Inc., Richmond, CA). Patients were divided into different groups in order to analyze date according to clinical and pathologic parameters. Since the distribution of hK11 mass per mg total protein in the ovarian tumor extracts was not Gaussian, the non- For survival analysis, 2 different end points, cancer relapse (either local recurrence or distant metastasis) and death, were used to calculate progression free (PFS) and overall survival (OS), respectively. PFS was defined as the time interval between the date of surgery and the date of identification of the recurrence of the metastatic disease. OS was defined as the time interval between the date of surgery and the date of death. The impact of hK11 on patient survival (PFS and OS) was assessed with the hazard ratio (HR), which was the relative risk of relapse or death in the hK11-positive group, calculated with the Cox univariate and multivariate proportional hazard regression model. 37 In the multivariate analysis, the clinical and pathologic variables that may affect survival, including age, stage of disease, tumor grade, histotype, and residual tumor size were adjusted.
Kaplan-Meier PFS and OS curves 38 were constructed to demonstrate survival differences between the hK11-positive and hK11-negative patients. The differences between the survival curves were tested for statistical significance using the log rank test. 39 Furthermore, the patients were divided into different subgroups based on disease stage, tumor grade and debulking success, and survival analysis was then repeated for each subgroup of patients.
RESULTS
Distribution of hK11 concentration in ovarian tumor extracts
hK11 concentration in ovarian tumor cytosols from 104 patients ranged from 0 -21 ng/mg of total protein, with a mean of 1.55 ng/mg total protein and a median of 0.54 ng/mg total protein (Table 1 ). An optimal cutoff value of 0.54 ng/mg total protein was identified by 2 analysis to distinguish hK11-positive from hK11-negative tumors (Fig. 1) and categorized 50% of tumors (50th percentile) as being hK11-positive.
Relationship between hK11 status and other clinicopathological variables
The distributions of various clinicopathologic variables between hK11-postitive and hK11-negative patients are summarized in hK11 concentration was significantly elevated in Stage I/II ovarian cancer cytosols compared to Stage III/IV (p ϭ 0.029, by the Mann Whitney U Test), indicating that a high hK11 concentration is associated with early stage disease (Fig. 2) .
Univariate and multivariate survival analysis
The strength of association between hK11 positivity and survival outcome is presented in Table 3 . In univariate analysis, hK11-positive patients had a significantly decreased risk of relapse (HR of 0.45, p ϭ 0.007) and death (HR of 0.34, p ϭ 0.005). The favorable effects of hK11 positivity on PFS and OS were lost, however, When hK11 was treated as a continuous variable. Only an association with OS remained (HR of 0.41, p ϭ 0.025) when survival outcomes were adjusted for all other variables in the multivariate analysis (i.e., Cox proportional hazard regression model). As expected, Kaplan-Meier survival curves (Fig. 3 ) also demonstrated that patients with hK11-positive tumors have longer PFS and OS (p ϭ 0.005 and p ϭ 0.003, respectively) compared to those who are hK11-negative.
Univariate and multivariate survival analysis in subgroups of patients
We further examined the associations between hK11 status and survival outcomes in subgroups of patients stratified by disease stage, tumor grade and debulking success (Table 4 ). Univariate analysis revealed that hK11 expression in patients with tumors of grades 1-2 possessed a higher OS than those with hK11-negative tumors (HR of 0.38, p ϭ 0.04). The differences in OS remained significant after the data were subjected to multivariate analysis when all other known prognostic variables are included. Further, in patients with optimal debulking success after surgery (Ͻ1 cm residual tumor), hK11 positivity correlated with a longer PFS in univariate and multivariate analysis (HR of 0.13, p ϭ 0.013, HR of 0.16, p ϭ 0.038, respectively).
Although marginally significant, patients with Stage I/II disease with hK11-positive ovarian tumors were less likely to relapse (HR of 0.11, p ϭ 0.052).
DISCUSSION
Ovarian cancer is the fourth most common (4%), fifth most lethal cancer (5%), and the most frequent cause of death from gynecologic cancer (53%) among U.S. women. 1 With a lack of early warning symptoms or reliable screening methods, the immediacy of discovering novel tumor markers to facilitate in the diagnosis and to provide insight regarding prognosis of established ovarian carcinoma becomes apparent. Measurements of single tumor markers have shown to be of insufficient sensitivity or specificity. Only in combination with CA-125 can they increase the sensitivity and specificity of detecting and monitoring ovarian carcinomas. 40, 41 The use of multiple tumor markers in parallel could potentially detect all neoplasms of varying histotypes and identify biologic profiles to predict disease outcome and employ effective, individualized therapeutic strategies.
Our study proposes that hK11 has prognostic significance in ovarian cancer. This serine protease is more frequently expressed in early stage (I-II) and grade (1-2) ovarian carcinomas and in women of pre-/peri-menopausal status who respond better to chemotherapy. The overexpression of hK11 in ovarian tumor cytosols is significantly associated with an increased PFS and OS in both univariate and multivariate analyses. hK11 positivity retained its independent prognostic value in the subgroup of patients with grades 1-2 tumors. Also, in patients with optimal debulking success (Ͻ1 cm residual tumor) after surgery, high hK11 levels predict favorable disease progression. Hence, hK11 is an independent indicator of favorable prognosis in ovarian cancer patients.
Previous studies have similarly shown that many other kallikrein genes (KLK4, 5, 6, 7, 8, 9, 14, and 15) are also differentially expressed in ovarian cancer and several possess clinical utility. 20 -24,42,43 Of relevance is the overexpression of KLK8, 9 and 14 in early stage ovarian tumors, which is associated with a favorable prognosis, analogous to hK11 in our study. Conversely, the remainder of the genes exhibit higher expression levels in advanced and more aggressive cancer and are associated with poor prognosis. Comparable investigations to determine the prognostic value of hK6 and hK10 in ovarian cancer cytosols also oppose the results obtained for hK11. That is, high levels of these kallikreins were associated with late stage disease and decreased disease-free and overall survival (Diamandis et al. 29 and our unpublished data). It is plausible to hypothesize, therefore, that human kallikreins function together in the normal physiology of the ovary and in promoting or inhibiting ovarian carcinogenesis at different stages. Other serine proteases, including trypsin, 44, 45 testisin, 46 hepsin, 47 and TADG-15 (tumor-associated differentially expressed gene 15) 48 in addition to human kallikreins are overexpressed in ovarian cancer. Thus, it would be appealing to study the overall panel of kallikrein and serine protease expression overall in this malignancy to determine the combined diagnostic or prognostic potential.
The overexpression of hK11 in early stage ovarian tumors, in addition to the elevation of hK11 in the serum of ovarian cancer patients, 29 indicates that KLK11 gene transcription is increased during ovarian carcinogenesis, suggesting a role for this protease in cancer progression. It was recently shown that KLK11 is under steroid hormone regulation, particularly estrogens. 29 Epidemiologic evidence implicates a role for endocrinologic factors, including estrogens, in the etiology of epithelial ovarian cancer. 49 In addition, 30 -63% of epithelial ovarian tumors express the estrogen receptor (ER), 50 a requirement for hormone responsiveness, and ER-␣ is markedly increased during ovarian carcinogenesis. 51 It is likely, therefore, that estrogen-ER complexes turn on KLK11 gene transcription leading to hK11 overexpression.
Estrogens appear to have a dual role in the progression of ER-positive and hormone responsive ovarian cancer cells in that they inhibit their invasion and motility and are mitogenic. 52, 53 The molecular mechanisms by which estrogens prevent local metastasis at early stages is unclear. These effects may be mediated by estrogen induced proteins, including compenents of the extracellular matrix, 54 serine protease inhibitors 55, 56 and serine proteases, including tissue-type plasminogen activator (t-PA), 57 which displays prognostic value in breast cancer. Taken together, it is not unreasonable to speculate that hK11, an estrogen induced protease, may play a role in the inhibition of ovarian cancer metastasis in early stage carcinomas by initiating or terminating certain pathologic events through the cleavage of specific substrates, including proteases, growth factors or oncogenes. This would be in agreement with the observation that hK11 overexpression in early stage ovarian cancer is an indicator of a favorable prognosis. Further basic and clinical studies are required to specify the activity of hK11 in both the normal and malignant ovary.
In summary, this is the first report attributing prognostic value to hK11 in ovarian cancer. Although its clinical utility is yet to be explored, it may be used in a panel with other kallikreins, serine proteases or biomarkers to improve its individual prognostic potential. It may have diagnostic potential in addition to its prognostic worth since hK11 is elevated in the serum of women with ovarian cancer. 
